Skip to main content
VISK
OTC Life Sciences

Viskase Q3 Loss Narrows, but Going-Concern Warning Flags August 2027 Debt Refinancing

Arie Shkolnikov · Analysis by Wiseek AI
Sentiment info
Negative
Importance info
8
Price
$4.098
Mkt Cap
$58.731M
52W Low
$1.5
52W High
$8.55
52W Position info
173% above low
Off High info
52% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

VISK has more than doubled off its 52-week low of $1.5 on light trading volume (0.3× avg).

Summary

Viskase posted a narrower third-quarter loss on 4.5% sales growth, but the 10-Q carries an explicit going-concern warning: the company must refinance its Senior Credit Facility before it matures in August 2027, with only $7.7 million of cash on hand.


Key Events · Earnings and Guidance · VISK

  • Going-Concern Warning on 2027 Debt Maturity

    The filing states substantial doubt exists about the Company's ability to continue as a going concern, dependent on refinancing the Senior Credit Facility before its August 2027 maturity.

  • Q3 Sales Up 4.5%, Gross Profit Up 45%

    Net sales rose to $95.279 million from $91.162 million, and gross profit rose to $8.503 million from $5.865 million, driven by North America volume recovery after the Osceola closure.

  • Cash Falls to $7.7 Million Against $135.7 Million Debt

    Cash and equivalents were $7.747 million at September 30, 2026 versus $9.217 million at December 31, 2025; total debt of $135.706 million is entirely classified as short-term, with $84.375 million of term loan maturing in 2027.

  • Operating Cash Flow Turns Negative

    Nine-month operating cash flow was negative $27.066 million versus positive $12.491 million a year earlier, driven by higher receivables, inventories and lower payables.


Analysis · VISK · Life Sciences

The quarter itself improved: sales rose 4.5% to $95.3 million and gross profit jumped 45% to $8.5 million as North America recovered from the Osceola plant closure. The filing's real news, however, is the explicit going-concern statement. Viskase must refinance its Senior Credit Facility before it matures in August 2027, and it has just $7.7 million of cash against $135.7 million of debt, all classified as short-term. Nine-month operating cash flow swung to negative $27.1 million from positive $12.5 million a year ago, so the company is burning cash while it negotiates. Management says it fully expects to complete the refinancing, but the auditors' standard is met: substantial doubt exists. For a $59 million market-cap company, the terms of that refinancing — or the absence of one — will determine whether equity has any value.

How filings like this one have moved

In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VISK was trading at $4.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $58.7M. The 52-week trading range was $1.50 to $8.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VISK - Latest Insights